Literature DB >> 2661197

Nitrate tolerance. A review of the evidence.

J T Flaherty1.   

Abstract

Organic nitrates are well established in the treatment of a wide variety of cardiovascular disorders, most notably angina pectoris and congestive heart failure. However, attenuation of, or tolerance to, haemodynamic and anti-ischaemic effects may occur with all long-acting nitrate formulations. In the majority of patients continuous administration of long acting nitrates tends to promote the development of attenuation, while intermittent administration avoids it. Likewise, higher-doses appear to induce attenuation to a greater degree than lower doses. Attenuation of haemodynamic effects and exercise tolerance in heart failure patients, and of clinical end-points in angina patients, appears to be less than attenuation of exercise testing end-points in angina patients. While the use of intermittent therapy avoids the development of attenuation, it may expose the patient to an as yet undefined risk of silent and/or symptomatic anginal episodes occurring during the nitrate-free interval. Likewise, the role of concomitant therapy in avoiding this potential risk remains to be defined. Means of avoiding attenuation may include the coadministration of sulfhydryl donors such as N-acetylcysteine. Alternatively, angiotension-converting enzyme (ACE) inhibitors such as captopril may block renin-angiotensin system-induced reflex sympathetic stimulation. Attenuation may occur to a greater or lesser degree in individual patients. The proportion of attenuators vs non-attenuators remains to be defined, as does a means of identifying such patients prospectively by clinical and/or laboratory parameters. Conflicting results among smaller studies may reflect variable proportions of attenuators vs non-attenuators. However, conflicting results among larger studies may reflect differences in patient selection criteria, such as selecting patients with positive and reproducible stress tests and little in the way of spontaneously occurring angina versus selecting patients with positive but variable stress tests and frequent episodes of spontaneously induced angina. The former group may reflect pure fixed coronary artery disease with little in the way of vasospasm, or change in vasomotor tone, while the latter group may reflect greater variability in vasomotor tone and/or more in the way of plaque instability. The clinical efficacy of long acting nitrates might therefore be expected to be greatest in those patients with larger numbers of spontaneously occurring angina episodes. Recent data suggest that nitrates may have important direct effects on coronary vessels including dilating eccentric coronary stenoses, dilating intercoronary collateral channels and having greater dilating effects on more diseased segments as opposed to less diseased coronary segments.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661197     DOI: 10.2165/00003495-198937040-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  135 in total

1.  Comparison of transdermal nitrate and isosorbide dinitrate in chronic stable angina.

Authors:  D P Nicholls; K Moles; D N Gleadhill; K Booth; J Rowan; P Morton
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

2.  Transmucosal and transdermal nitroglycerin delivery systems for prevention of chronic stable angina pectoris.

Authors:  N S Khurmi; M J O'Hara; M J Bowles; J R Whittington; A Lahiri; E B Raftery
Journal:  Br J Clin Pract       Date:  1986-05

3.  The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance.

Authors:  S Silber; A C Vogler; K H Krause; K Theisen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm.

Authors:  D T Mason; E Braunwald
Journal:  Circulation       Date:  1965-11       Impact factor: 29.690

5.  Anti-ischemic effects of an 80-mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80 mg once daily or twice daily.

Authors:  S Silber; K H Krause; C Garner; K Theisen; H Jahrmärker
Journal:  Z Kardiol       Date:  1983

6.  Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure.

Authors:  N Sharpe; R Coxon; M Webster; R Luke
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

Review 7.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

8.  Vascular smooth muscle relaxation by nitro compounds: reduced relaxation and cGMP elevation in tolerant vessels and reversal of tolerance by dithiothreitol.

Authors:  K L Axelsson; R G Andersson; J E Wikberg
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-05

9.  Sustained effects of transdermal nitroglycerin in patients with angina pectoris.

Authors:  A S Kapoor; N S Dang; R D Reynolds
Journal:  Clin Ther       Date:  1985       Impact factor: 3.393

10.  Role of nitrates in congestive heart failure.

Authors:  J N Cohn
Journal:  Am J Cardiol       Date:  1987-11-16       Impact factor: 2.778

View more
  15 in total

Review 1.  Development of long-acting nitrate delivery systems.

Authors:  U E Jonsson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Causes and problems of nonresponse or poor response to drugs.

Authors:  P Salvà Lacombe; J A García Vicente; J Costa Pagès; P Lucio Morselli
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 3.  Medical management of congestive heart failure.

Authors:  A E Arai; B H Greenberg
Journal:  West J Med       Date:  1990-10

Review 4.  Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil.

Authors:  A H Gomma; H J Purcell; K M Fox
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation.

Authors:  Manesh R Patel; Matthew T Roe
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Nicorandil ameliorates ischaemia-reperfusion injury in the rat kidney.

Authors:  Shogo Shimizu; Motoaki Saito; Yukako Kinoshita; Fumiya Ohmasa; Fotios Dimitriadis; Kohei Shomori; Atsushi Hayashi; Keisuke Satoh
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

7.  Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.

Authors:  Xian-Liang Tang; Yu-Ting Xuan; Yanqing Zhu; Gregg Shirk; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-18       Impact factor: 4.733

Review 8.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 9.  Vasodilators. A re-evaluation of their role in heart failure.

Authors:  L W Stevenson; G Fonarow
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 10.  The high-risk unstable angina patient. An approach to treatment.

Authors:  S Kar; Y Wakida; R Nordlander
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.